Cybin’s CEO, Doug Drysdale, shares update on sublingual psilocybin treatment for depression, and more.
Cybin’s CEO, Doug Drysdale, shares update on sublingual psilocybin treatment for depression, and more.
In today’s episode of the Psychedelic Spotlight podcast, we sit down with Doug Drysdale, CEO of Cybin, a biotechnology company focused on creating new, effective, and accessible psychedelic-based therapies.
In our conversation, Doug talks about the company’s mission to revolutionize mental healthcare, how Cybin is delivering powerful and effective therapies, and why being the first psychedelic-based company to list on the New York Stock Exchange was a natural fit. Cybin can be found on the NYSE under the ticker symbol $CYBN.
*To learn more about Cybin and the work they’re doing, visit their website: Cybin.com
Tim Ferriss and Michael Pollan Team Up to Launch UC Berkeley Psychedelic Journalism...